Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.

A molecular complex comprising a therapeutic agent and a controlled release construct, the controlled release construct comprising a primary matrix conjugation site which is linked to an cell adhesive site, via a binding region and optionally via one or more spacer elements, wherein the binding region has a folded configuration in which it is bound to the therapeutic agent, wherein the construct is configured such that when mechanical tension is applied between the primary matrix conjugation site and the cell adhesive site, the binding region adopts a less folded configuration in which bound therapeutic agent is released. Related controlled release constructs for loading with the therapeutic agent, pharmaceutical compositions and methods of manufacture and use.

A molecular complex comprising a therapeutic agent and a controlled release construct, the controlled release construct comprising a primary matrix conjugation site which is linked to an cell adhesive site, via a binding region and optionally via one or more spacer elements, wherein the binding region has a folded configuration in which it is bound to the therapeutic agent, wherein the construct is configured such that when mechanical tension is applied between the primary matrix conjugation site and the cell adhesive site, the binding region adopts a less folded configuration in which bound therapeutic agent is released. Related controlled release constructs for loading with the therapeutic agent, pharmaceutical compositions and methods of manufacture and use.

Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.

Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.

The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29h. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.

The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29h. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.

The present invention relates to payloads containing functionalized platinum-(benz)acridine hybrid agents as cytotoxic warheads and a method of synthesizing the payloads. The payload can be regioselectively conjugated to a biologically active moiety in order to facilitate the delivery and/or enhance the activity of the platinum compound.

The present invention relates to payloads containing functionalized platinum-(benz)acridine hybrid agents as cytotoxic warheads and a method of synthesizing the payloads. The payload can be regioselectively conjugated to a biologically active moiety in order to facilitate the delivery and/or enhance the activity of the platinum compound.

The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein m, n, p, and q represent integers and are selected from 0 and 1; and r is comprised from 1 to 10; a linker birradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position i in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position i+4 or i+7 in the peptide sequence of formula (I); a C-terminal end corresponding to C(O)R.sub.4; and a N-terminal end corresponding to NHR.sub.5. Alternatively, the present invention provides a peptide or a pharmaceutical salt thereof which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 9: The peptides of the invention show anticancer activity. (I)

TABLE-US-00001 (I) [(Glu)m-(Lys)n-Ala-Ala-Lys-Val-Val-Ile-Leu-Lys- Lys-Ala-Thr-Glu-Tyr-Val-(His)p-(Ser)q].sub.r-